# Oakwood Medical Investors

Oakwood Medical Investors is a Private Equity based in St. Louis, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** St. Louis, United States
- **Region:** North America
- **Address:** St. Louis, MO, United States
- **Assets under management:** Undisclosed
- **Website:** oakwoodmedical.com

## Regulatory record

- **Reports private funds:** No

## About

Oakwood Medical Investors is a life sciences venture capital fund investing in development stage medical device, biopharmaceutical and healthcare service companies. The firm has made 62 investments, including a Series A - III investment in Elira on November 14, 2019. Oakwood Medical Investors has 15 portfolio exits, with EndoGastric Solutions being their latest exit on July 01, 2024.

## Sectors

- Digital Health
- Healthcare Services
- Medical Devices

## Questions

### Who runs investment decisions at Oakwood Medical Investors?

Raul D. Recarey, the firm's founder, serves as the central investment decision-maker. Recarey brings an operating background in medical device commercialization, which shapes the firm's clinical-first due-diligence process. Oakwood's lean partnership structure means Recarey personally leads or co-leads the majority of the firm's transactions rather than delegating to a large investment committee.

### How does Oakwood Medical Investors source proprietary deal flow?

Oakwood sources opportunities through Recarey's relationships with academic medical centers, surgeon-inventors, and regulatory consultants. The firm's St. Louis location provides proximity to Midwestern research institutions in the orthopedic and cardiovascular space, while its narrow sub-sector focus — electrophysiology, spine, wound care — means referrals come from a tight network of clinicians who recognize Oakwood's technical fluency.

### Does Oakwood participate in fund commitments or only direct deals?

Oakwood operates as a direct investor, taking lead or co-lead equity positions in portfolio companies rather than committing to external venture funds. There is no public record of the firm acting as a limited partner in other managers' vehicles. Its model relies on board-level engagement and hands-on regulatory support.

### Which sectors does Oakwood Medical Investors explicitly avoid?

Oakwood concentrates on medical devices, diagnostics, and digital health. The firm does not have a public track record in biopharmaceuticals, drug discovery platforms, or later-stage healthcare services roll-ups. Its avoidance of small-molecule therapeutics distinguishes it from generalist life-science VC firms and reflects Recarey's device-industry operating roots.

## Related profiles

- [Oakwest Corporation](https://altss.com/profile/oakwest-corporation)
- [Oberndorf Ventures](https://altss.com/profile/oberndorf-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/oakwood-medical-investors

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology